

Cancers of the Oesophagus and Stomach: Additional Insight from the Oral Cavity- Mini Review

SUMMARY

Periodontitis as a chronic infection that affects between 10 and 15 percent of the world's population. It is characterized by the loss of connective tissue attachment and alveolar bone. Periodontitis and the resulting systemic inflammation are associated with numerous systemic diseases such as cardiovascular disease, diabetes, chronic kidney disease, rheumatoid, arthritis, respiratory diseases, impairment of cognitive function. The exact mechanism of the association between periodontitis and UGI cancers is not known, but may include direct bacterial ingestion, chronic inflammation, and immune modulation. Considering that about 15% of tumors are the result of chronic inflammation, it is necessary to examine in detail the relationship between chronic periodontal disease and UGI cancer. Specifically, keystone periodontal pathogens, including Porphyromonas gingivalis and Treponema denticola may react with the molecular hallmarks of gastrointestinal cancers, triggering mutations, and generate a permissive immune microenvironment by impairing anti-tumor checkpoints.

Key words: UGI Cancers, Periodontitis, *Helicobacter pylori*

Kulić Milan¹, Ilić Bojana², Marinković Jelena²

¹ Clinical Hospital Center "Dr Dragiša Mišović – Dedinje", Belgrade, Serbia

² Department of Physical Chemistry, "Vinča"

¹ Institute of Nuclear Sciences – National Institute of the Republic of Serbia, University of Belgrade, Belgrade, Serbia

REVIEW PAPER (RP)

Balk J Dent Med, 2025;43-46

Introduction

Upper Gastrointestinal (UGI) cancers consider malignancies of the digestive tract and its accessory organs, i.e cancers of oesophagus, stomach, small intestine, pancreatic cancer, liver cancer and cancers of the biliary system¹. Among them, cancers of the stomach and oesophagus are the third and sixth leading causes of cancer mortality in the world, respectively².

Oesophageal cancer is represented by the two main histological subtypes squamous cell carcinoma and adenocarcinoma. Squamous oesophageal cancer is the most common type in the Western countries. This disease is about 3 times more common among African Americans, and also 3 times more common in men in the USA. The most common type of oesophagus cancer in White Americans is adenocarcinoma, contrary to squamous cell carcinoma observed in African Americans. Oesophagus cancer is 10 to 100 times more common in Asia and the southern Africa than in the United States. Stomach

carcinoma is mostly histologically represented by the adenocarcinoma type^{2,3}.

Cancer etiology is in general multifactorial, but tobacco smoking and alcohol intake are consider to be of the utmost importance for elevated incidence of both oesophagus and stomach cancers^{4,5}. Association of the dietary habits and development of the UGI cancers was in the focus of many studies. It was suggested that drinking of hot and strong tea statistically significant increased risk of both cancers.

Concerning eating of fried and spicy food, or barbecuing meat, it was previously associated with the increased risk of the esophageal cancer⁶⁻⁸, but this was refuted by the novel work of Ibebiele et al.⁵. In case of gastric cancer, it was also reported that daily consumption of red meat and dairy products along with habitual salt intake and spicy food intake are in line with the increased risk for gastric cancer^{4,9,10}. This was explained by irritation of the stomach wall leading to the development of cancer^{4,11}. Further, it was also suggested that overeating

and/or a high meal frequency (>3 times/day) is in line with increased risk of gastric cancer. This was explained by physical damage to the gastric mucosa caused by repetitions of compulsory expansion of the stomach lining⁴.

Genetic factors are also considered to be involved in the etiology of both cancers. In case of oesophagus cancer their influence seems to be generally low³. Similarly, hereditary gastric cancers are considered to contribute approximately 1-3% of total cases of stomach cancers and it typically develops at a younger age^{11,12}. On the other hand, considerably significant number of gastric cancers is *Helicobacter pylori* (*H. pylori*) and Epstein Barr virus (EBV) infections¹³. It was suggested that *H. pylori* infection affects immune mediated reaction in the gastric mucosal cells¹⁴, while EBV upregulation of genes with pro-tumor and anti-apoptotic activity¹⁵.

The prognoses of oesophagus and gastric cancers are in general poor, despite the available surgical or other techniques such as radiation, chemotherapy, and targeted drug therapies¹. An overall 5-year survival of the patients suffering from stomach cancer is approx. 42.9%¹⁶, while in case of the oesophagus it is below 20%³. For that reason identifying the risk or causative factors is important to prevent afore-mentioned cancers¹⁷. Concerning a fact that novel literature data are dedicated to explore the link between oral health and cancers of esophagus and stomach this review will put the special focus on that.

Periodontitis and UGI Cancers: Can the Link be made?

Periodontitis as a chronic infection that affects up to 50 % of the world's population. It is characterized by the loss of connective tissue attachment and alveolar bone¹⁸. The main risk factors of periodontitis are the poor oral hygiene (accumulation of subgingival plaques), smoking, diabetes, usage of the certain medications, age and stress¹⁸. The presence of certain microorganisms, especially anaerobic gram-negative bacteria in subgingival plaques significantly contributes to the progression of periodontitis.

Although the exact mechanism of the association between periodontitis and UGI cancers is not known, the several mechanisms have been proposed so far. Firstly, oral bacteria and their products may be directly ingested and may modify the present microbiome and activate the inflammasome complex generating the pathological processes¹⁹. The second mechanism implies immune regulation by inducing T helper 17 (Th17). These cells are able to migrate to the intestinal lymph nodes, and stimulated by ingested oral bacteria may cause inflammation¹⁹. Importantly, recent study shows that these processes may have bidirectional effect. And thirdly, systemic inflammation induced by periodontitis, disrupting the gastric barrier, increasing the local oxidative stress and bypassing immunogenic response.

A significant increase in the systemic inflammation markers C-reactive protein and interleukin-6 in patients with periodontal diseases was confirmed². While significant reduction of the systemic inflammation markers was obtained when the periodontal therapy was applied², all demonstrating that periodontitis may add to the systemic inflammatory burden of effective individuals. Considering that about 15% of tumors are the result of chronic inflammation, it is necessary to examine in detail the immunological relationship between chronic periodontal disease and UGI cancer.

Periodontal pathogens and UGI cancers

The main bacteria linked to the periodontitis are *Porphyromonas gingivalis*, *Actinobacillus actinomycetemcomitans*, *Tannerella forsythensis*, *Treponema denticola* and *Fusobacterium nucleatum*¹⁸.

Literature review suggested that patients with gastric cancer experience a high level of bleeding on probing, high levels of *T. denticola* and *A. actinomycetemcomitans* (periodontal disease associated microorganisms) and less bacterial diversity in saliva and dental plaque compared to healthy individuals. Mechanisms linked between above mentioned periodontal pathogens and UGI cancers were dentilisin degradation of IL-8 and TNF- α , cleavage of pro-MMP-8 and 9¹⁹. It is also proven that *P. gingivalis* and *T. denticola* (periodontal disease associated microorganisms) stimulate chronic inflammation by adhesion to keratinocytes, invasion and induction of NF-kB pathway which can contribute to carcinogenesis. These oral pathogens have been detected in oesophageal and gastric cancer tissues as well¹⁹. Moreover, oral bacteria may also generate carcinogenic metabolites, such as *Streptococcus mutans* that reduces nitrate to nitrite, precursors to nitrosamines associated with oesophageal cancer¹⁹. The study of Ahn et al. investigated the relationship of serum antibody levels of *P. gingivalis* with orodigestive cancer mortality²⁰. The authors concluded the higher rate of orodigestive cancers in patients with periodontitis, as well as the fact that mortality increased with the severity of periodontal disease²⁰.

Recent studies showed the intention of the researchers to understand the link between the oral status of the patient and its susceptibility to the above mentioned cancers. Undoubtedly it was suggested that poor oral health, indicated by the presence of periodontitis and leading to the tooth loss, has been linked with increased risk of various cancer types, including UGI cancers. Interestingly, the overall mean number of lost teeth that was linked to UGI cancers was 18.3. The protective effects of tooth brushing was emphasized and attributed to the removal of dental plaque, including removal of afore mentioned bacteria². Overall, daily tooth brushing was related to reduced risk of developing UGI cancers with a linear trend. Daily tooth brushing (vs. never) was linked

with a significantly risk reduction for oesophageal cancer while for gastric cancer, daily tooth brushing (vs. never) was marginally associated with a lower risk². Regarding the tooth, significant linear trend for both UGI cancers was observed. In addition, the highest the tooth loss was, it was linked with an approximately 60% higher risk for both oesophageal and gastric cancers.

H. pylori as periodontal pathogen

Helicobacter pylori as a gram negative bacterium was classified as a Group 1 carcinogen by The International agency for research on cancer classified²¹. In 1989, Krayden et al.²² isolated *H. pylori* from the dental plaque, and then its presence in saliva was confirmed by Ferguson et al.²³. Since then, *H. pylori* was associated with different oral diseases, including halitosis, caries, recurrent oral ulcers, chronic gingivitis and periodontitis. Studies have indicated that *H. pylori* rate in patients with periodontitis is higher compared to periodontally healthy individuals^{24,25}. Taking into account that more than 50% of the global population suffers from periodontitis, it is of the most importance to determine the connection with *H. pylori* induced periodontitis and UGI cancers.

Today, it has been established that certain types of *H. pylori* have different virulence and hence may be causative of periodontitis. There are two genes associated with the *H. pylori* virulence: vacuolating cytotoxin gene A (vacA) and cytotoxin-associated gene A (cagA)²⁶, responsible for damaging the lysosome and endoplasmic reticulum. The cagA gene has been confirmed to cause cellular inflammation by interfering with the EMT-associated signaling pathway, miRNA-584, miRNA-1290. Also a combination of the two most important alleles, the signal peptide region (s region) and the middle region (m region) define the virulence of *H. pylori*: s1m1 > s1m2 > s2m1 > s2m2 from strong to weak, accordingly²⁶.

The study by Zheng and Zhou confirmed the significant presence of cagA gene of *H. pylori* in patients with moderate or severe periodontitis, i.e. correlation with *H. pylori* infection²⁷. *H. pylori* is statistically significantly more present in the stomach of patients who have the same in subgingival plaques, which led to the conclusion that the oral environment is the source of the same bacteria. Therefore, the *H. pylori* control in the subgingival plaques must be taken into account during therapy²⁸.

Conclusions

Keystone periodontal pathogens, including *Porphyromonas gingivalis* and *Treponema denticola* may interact with the molecular hallmarks of gastrointestinal cancers, inducing genomic mutations, and promote a permissive immune microenvironment by impairing

anti-tumor checkpoints. The exact mechanism of the association between periodontitis and UGI cancers is not known, but may include direct bacterial ingestion, chronic inflammation, and immune modulation. Further research must be focused on the biomarkers detections reflecting this interactions and explore local treatment modalities that may affect general status of the patient.

References

1. Li Y, Duan HY, Yang KD, Ye JF (2023). "Advancements and challenges in oncolytic virus therapy for gastrointestinal tumors". *Biomed Pharmacother.* **168**: 115627. doi: 10.1016/j.biopha.2023.115627. PMID: 37812894.
2. Yano Y, Abnet CC, Poustchi H, Roshandel G, Pourshams A, Islami F, et al. (2021). "Oral Health and Risk of Upper Gastrointestinal Cancers in a Large Prospective Study from a High-risk Region: Golestan Cohort Study". *Cancer Prev Res (Phila)*. **14** (7): 709-718. doi: 10.1158/1940-6207.CAPR-20-0577. PMID: 33731409.
3. Xie SH, Lagergren J (2018). "Risk factors for oesophageal cancer". *Best Pract Res Clin Gastroenterol.* **36-37**: 3-8. doi: 10.1016/j.bpg.2018.11.008. PMID: 30551854.
4. Kim SY, Kwak JH, Eun CS, Han DS, Kim YS, Song KS, et al. (2022). "Gastric Cancer Risk Was Associated with Dietary Factors Irritating the Stomach Wall: A Case-Control Study in Korea". *Nutrients*. **14** (11): 2233. doi: 10.3390/nu14112233. PMID: 35684033.
5. Ibiebele TI, Taylor AR, Whiteman DC, van der Pols JC (2010). "Eating habits and risk of esophageal cancers: a population-based case-control study". *Cancer Causes Control*. **21** (9): 1475-1484. doi: 10.1007/s10552-010-9576-8. PMID: 20467799.
6. Castelletto R, Castellsague X, Muñoz N, Iscovich J, Chopita N, Jmelnitsky A (1994). "Alcohol, tobacco, diet, mate drinking, and esophageal cancer in Argentina". *Cancer Epidemiol Biomarkers Prev*. **3** (7): 557-564. PMID: 7827585.
7. De Stefani E, Muñoz N, Estève J, Vasallo A, Victora CG, Teuchmann S (1990). "Mate drinking, alcohol, tobacco, diet, and esophageal cancer in Uruguay". *Cancer Res*. **50** (2): 426-431. PMID: 2295081.
8. Ward MH, Sinha R, Heineman EF, Rothman N, Markin R, Weisenburger DD, et al. (1997). "Risk of adenocarcinoma of the stomach and esophagus with meat cooking method and doneness preference". *Int J Cancer*. **71** (1): 14-9. doi: 10.1002/(sici)1097-0215(19970328)71:1<14::aid-ijc4>3.0.co;2-6. PMID: 9096659.
9. Guggenheim DE, Shah MA (2013). "Gastric cancer epidemiology and risk factors". *J Surg Oncol*. **107** (3): 230-236. doi: 10.1002/jso.23262. PMID: 23129495.
10. Phan J, Benhammou JN, Pisegna JR (2015). "Gastric Hypersecretory States: Investigation and Management". *Curr Treat Options Gastroenterol*. **13** (4): 386-397. doi: 10.1007/s11938-015-0065-8. PMID: 26342486.

11. Slavin TP, Weitzel JN, Neuhausen SL, Schrader KA, Oliveira C, Karam R (2019). „Genetics of gastric cancer: what do we know about the genetic risks?” *Transl Gastroenterol Hepatol.* 4: 55. doi: 10.21037/tgh.2019.07.02. PMID: 31463414.
12. Blair VR, McLeod M, Carneiro F, Coit DG, D’Addario JL, van Dieren JM, et al. (2020). “Hereditary diffuse gastric cancer: updated clinical practice guidelines”. *Lancet Oncol.* 21 (8): e386-e397. doi: 10.1016/S1470-2045(20)30219-9. PMID: 32758476.
13. Rihane FE, Erguibi D, Elyamine O, Abumsimir B, Ennaji MM, Chehab F (2021). “*Helicobacter pylori* co-infection with Epstein-Barr virus and the risk of developing gastric adenocarcinoma at an early age: Observational study infectious agents and cancer”. *Ann Med Surg (Lond).* 68: 102651. doi: 10.1016/j.amsu.2021.102651. PMID: 34386233.
14. Ford AC, Yuan Y, Moayyedi P (2020). “*Helicobacter pylori* eradication therapy to prevent gastric cancer: systematic review and meta-analysis”. 69 (12): 2113e2121. doi: org/10.1136/gutjnl-2020-320839.
15. Tavakoli A, Monavari SH, Solaymani Mohammadi F, Kiani SJ, Armat S, Farahmand M (2020). “Association between Epstein-Barr virus infection and gastric cancer: a systematic review and meta-analysis”. *BMC Cancer.* 20 (1): 493. doi: 10.1186/s12885-020-07013-x. PMID: 32487043.
16. Li Y, Feng A, Zheng S, Chen C, Lyu J (2022). “Recent Estimates and Predictions of 5-Year Survival in Patients with Gastric Cancer: A Model-Based Period Analysis”. *Cancer Control.* 29: 10732748221099227. doi: 10.1177/10732748221099227. PMID: 35499497.
17. Lee K, Lee JS, Kim J, Lee H, Chang Y, Woo HG, et al. (2020). “Oral health and gastrointestinal cancer: A nationwide cohort study”. *J Clin Periodontol.* 47 (7): 796-808. doi: 10.1111/jcpe.13304. PMID: 32385894.
18. Gasner NS, Schure RS (2023). “Periodontal Disease”. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; PMID: 32119477.
19. Baima G, Ribaldone DG, Muwalla M, Romano F, Citterio F, Armandi A, et al. (2021). “Can Periodontitis Affect the Health and Disease of the Digestive System? A Comprehensive Review of Epidemiological Evidence and Biological Mechanisms”. *Curr. Oral Health Rep.* 8: 96–106. doi: 10.1007/s40496-021-00302-9.
20. Ahn J, Segers S, Hayes RB (2012). “Periodontal disease, Porphyromonas gingivalis serum antibody levels and orodigestive cancer mortality”. *Carcinogenesis.* 33 (5): 1055-1058. doi: 10.1093/carcin/bgs112. PMID: 22367402.
21. Handa O, Naito Y, Yoshikawa T (2011). “Redox biology and gastric carcinogenesis: the role of *Helicobacter pylori*”. *Redox Rep.* 16 (1): 1-7. doi:10.1179/174329211X12968219310756. PMID: 21605492.
22. Krajden S, Fuksa M, Anderson J, Kempston J, Boccia A, Petrea C, et al. (1989). “Examination of human stomach biopsies, saliva, and dental plaque for *Campylobacter pylori*”. *J Clin Microbiol.* 27 (6): 1397-1398. doi: 10.1128/jcm.27.6.1397-1398.1989. PMID: 2754008.
23. Ferguson DA Jr, Li C, Patel NR, Mayberry WR, Chi DS, Thomas E (1993). “Isolation of *Helicobacter pylori* from saliva”. *J Clin Microbiol.* 31 (10): 2802-2804. doi: 10.1128/jcm.31.10.2802-2804.1993. PMID: 8253990.
24. Anand PS, Kamath KP, Anil S (2014). “Role of dental plaque, saliva and periodontal disease in *Helicobacter pylori* infection”. *World J Gastroenterol.* 20 (19): 5639-5653. doi: 10.3748/wjg.v20.i19.5639. PMID: 24914323.
25. Silva DG, Stevens RH, Macedo JM, Albano RM, Falabella ME, Fischer RG, et al. (2010). “Presence of *Helicobacter pylori* in supragingival dental plaque of individuals with periodontal disease and upper gastric diseases”. *Arch Oral Biol.* 55 (11): 896-901. doi: 10.1016/j.archoralbio.2010.06.018. PMID: 20863482.
26. Backert S, Tegtmeyer N (2010). “The versatility of the *Helicobacter pylori* vacuolating cytotoxin vacA in signal transduction and molecular crosstalk”. *Toxins (Basel).* 2 (1): 69-92. doi: 10.3390/toxins2010069. PMID: 22069547.
27. Zheng P, Zhou W (2015). “Relation between periodontitis and *helicobacter pylori* infection”. *Int J Clin Exp Med.* 8 (9): 16741-16744. PMID: 26629215.
28. Yuksel Sert S, Ozturk A, Bektas A, Cengiz MI (2019). “Periodontal treatment is more effective in gastric *Helicobacter pylori* eradication in those patients who maintain good oral hygiene”. *Int Dent J.* 69 (5): 392-399. doi: 10.1111/idj.12484. PMID: 31038210.

Received on August 29, 2024.

Revised on September 10, 2024.

Accepted on September 20, 2024.

Conflict of Interests: Nothing to declare.

Financial Disclosure Statement: Nothing to declare.

Human Right Statement: None required.

Animal Rights Statement: None required.

Correspondence

Jelena Marinković

VINČA Institute of Nuclear Sciences – National Institute of the Republic of Serbia

University of Belgrade, Serbia

e-mail: jelena.marinkovic@vin.bg.ac.rs